Welcome to our dedicated page for BIOVAXYS TECHNOLOGY news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BIOVAXYS TECHNOLOGY stock.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform. They focus on treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company has a range of products in their clinical stage pipeline, including maveropepimut-S and BVX-0918, which target different types of cancers like Diffuse Large B Cell Lymphoma (DLBCL) and ovarian cancer. BioVaxys also capitalizes on its tumor immunology expertise to identify new targetable tumor antigens using predictive algorithms and other technologies.
Rhea-AI Summary
BioVaxys Technology Corp. announced that the Ontario Securities Commission granted a management cease trade order due to delayed financial filings. The delay was caused by additional information needed for audits and recent acquisitions. The Company expects to file the Required Reports within 30 days of the original deadline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. receives a Notice of Allowance from the Japanese Patent Office for a Patent related to inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. The DPX™ platform attracts antigen presenting cells to the injection site, enhancing immune response. BioVaxys also files an international patent application for methods of formulating DPX™ compositions with lipid-based and polynucleotide adjuvants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. completes a non-brokered private placement, raising $501,500 through 16,716,666 Units at $0.03 per Unit. Each Unit includes a Common Share and a Warrant. The Company plans to utilize the proceeds for working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. completes the first tranche of a non-brokered private placement, raising $1,103,500 through the issuance of 36,783,334 Units at $0.03 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.05. The Company plans to use the proceeds for working capital, with the second tranche expected to close by February 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
Rhea-AI Summary
BioVaxys Technology Corp. completes the first tranche of a non-brokered private placement, raising $1,103,500 through the issuance of 36,783,334 Units at $0.03 per Unit. Each Unit includes one Common Share and one Warrant. The Company plans to use the net proceeds for working capital and anticipates closing the second tranche by February 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.11%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares at a deemed price of $0.03 per common share. The debt did not include accrued salaries to officers or directors, nor payments for Investor Relations Activities. Certain related parties, including BioVaxys CEO James Passin and COO and President Kenneth Kovan, participated in the debt settlement. The securities issued are subject to a four-month hold period from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has announced the execution of a non-binding Letter of Intent to acquire a core platform technology and entire immunotherapeutics intellectual property portfolio in oncology and other immunological fields. The company has been granted exclusivity while working on the drafting of a definitive agreement with an unnamed biotechnology company's former secured creditor. Investors are advised to use caution in trading the company's shares while discussions are underway, as there is no certainty of reaching a definitive acquisition agreement or completing any transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.53%
Tags
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) announced the termination of the US Distribution Agreement for Papilocare and Immunocaps with Procare Health, while the EU clinical development partnership for their ovarian cancer vaccine BVX-0918 remains unchanged. This move allows BioVaxys to refocus on immunotherapeutics, strengthening their balance sheet and advancing initiatives related to immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.53%
Tags
FAQ
What is the current stock price of BIOVAXYS TECHNOLOGY (BVAXF)?
The current stock price of BIOVAXYS TECHNOLOGY (BVAXF) is $0.0475 as of December 20, 2024.
What is the market cap of BIOVAXYS TECHNOLOGY (BVAXF)?
The market cap of BIOVAXYS TECHNOLOGY (BVAXF) is approximately 11.7M.
What is BioVaxys Technology Corp focused on?
BioVaxys Technology Corp is dedicated to improving patient lives with immunotherapies for cancers, infectious diseases, antigen desensitization, and other immunological fields.
What are some products in BioVaxys' clinical stage pipeline?
BioVaxys has products like maveropepimut-S and BVX-0918 in its clinical stage pipeline, targeting cancers such as Diffuse Large B Cell Lymphoma (DLBCL) and ovarian cancer.
How does BioVaxys identify new targetable tumor antigens?
BioVaxys uses its tumor immunology expertise, along with predictive algorithms and other technologies, to identify new targetable tumor antigens.
BIOVAXYS TECHNOLOGY CORP